Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 18,503,128 | 0 | - | - | Common Stock | |
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 17,070,904 | 0 | - | - | Common Stock | |
| Metsera Inc | Clive A. Meanwell | Director, EXECUTIVE CHAIRMAN | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 12,767,462 | 0 | - | - | Common Stock | |
| Metsera Inc | Christopher Whitten Bernard | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 12,767,462 | 0 | - | - | Common Stock | |
| Metsera Inc | Paul L. Berns | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 8,313,680 | 0 | - | - | Common Stock | |
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 8,313,680 | 0 | - | - | Common Stock | |
| Metsera Inc | Paul L. Berns | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 7,523,682 | 0 | - | - | Common Stock | |
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 7,523,682 | 0 | - | - | Common Stock | |
| UWM Holdings Corp (Class A) | Mathew Ishbia | Director, President and CEO, Ten Percent Owner | 13 Nov 2025 | 6,800,000 | 1,338,282,620 | - | - | UWM Paired Interests | ||
| UWM Holdings Corp (Class A) | Mathew Ishbia | Director, President and CEO, Ten Percent Owner | 13 Nov 2025 | 6,800,000 | 8,261,764 | - | - | Class A Common Stock | ||
| Biohaven Ltd | John W. Childs | Director | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 13 Nov 2025 | 3,333,333 | 5,653,904 | - | 7.5 | 24,999,998 | Common Shares |
| V2X Inc | Dino M. Cusumano | Director | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 13 Nov 2025 | 2,250,000 | 5,750,001 (49%) | 19% | 55 | 123,750,000 | Common Stock |
| CoreWeave Inc (Class A) | Jack Cogen | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 2,000,000 | 0 | - | 0 | Class A Common Stock | |
| CoreWeave Inc (Class A) | Jack Cogen | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 1,800,000 | 200,000 | - | 0 | Class A Common Stock | |
| Metsera Inc | Christopher Whitten Bernard | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 1,702,328 | 0 | - | - | Stock Option (right to buy) | |
| Cricut Inc (Class A) | Ashish Arora | Director, Chief Executive Officer, Ten Percent Owner | 13 Nov 2025 | 1,547,295 | 22,007,506 | - | - | Class B Common Stock | ||
| Cricut Inc (Class A) | Ashish Arora | Director, Chief Executive Officer, Ten Percent Owner | 13 Nov 2025 | 1,547,295 | 4,490,441 | - | - | Class A Common Stock | ||
| Roivant Sciences Ltd | Vivek Ramaswamy | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 13 Nov 2025 | 1,027,670 | 34,193,406 | - | 20.3 | 20,892,531 | Common Shares |
| Assertio Holdings Inc | Mark L. Reisenauer | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) | |
| CoreWeave Inc (Class A) | Michael Intrator | Director, CEO and President, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 1,000,000 | 5,991,055 | - | 0 | Class A Common Stock | |
| Metsera Inc | Paul L. Berns | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 957,559 | 0 | - | - | Common Stock | |
| Metsera Inc | Steven Marso | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 829,885 | 0 | - | - | Stock Option (right to buy) | |
| Nukkleus Inc - Ordinary Shares - New | Menachem Shalom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 750,000 | 1,250,000 | - | 0 | Common Stock, $0.0001 par value per share | |
| Vyome Holdings Inc | Shiladitya Sengupta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 624,432 | 624,432 | - | - | Stock Option (right to buy) | |
| Vyome Holdings Inc | Venkateswarlu Nelabhotla | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 615,149 | 615,149 | - | - | Stock Option (right to buy) | |
| UWM Holdings Corp (Class A) | Mathew Ishbia | Director, President and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 5.27 per share. | 13 Nov 2025 | 596,356 | 2,058,120 | - | 5.3 | 3,142,796 | Class A Common Stock |
| UWM Holdings Corp (Class A) | Mathew Ishbia | Director, President and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 4.94 per share. | 13 Nov 2025 | 596,356 | 7,665,408 | - | 4.9 | 2,945,999 | Class A Common Stock |
| UWM Holdings Corp (Class A) | Mathew Ishbia | Director, President and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 5.11 per share. | 13 Nov 2025 | 596,356 | 1,461,764 | - | 5.1 | 3,047,379 | Class A Common Stock |
| Roivant Sciences Ltd | Vivek Ramaswamy | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.51 per share. | 13 Nov 2025 | 539,650 | 33,653,756 | - | 20.5 | 11,068,222 | Common Shares |
| Assertio Holdings Inc | Mark L. Reisenauer | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 500,000 | 500,000 | - | - | Restricted Stock Units | |
| Codexis Inc | Alison Moore | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Biohaven Ltd | Gregory Hugh Bailey | Director | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 13 Nov 2025 | 400,000 | 2,020,071 | - | 7.5 | 3,000,000 | Common Shares |
| Metsera Inc | Christopher Whitten Bernard | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 348,750 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Christopher J. Visioli | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 340,465 | 0 | - | - | Stock Option (right to buy) | |
| LAVA Therapeutics NV | Stephen A. Hurly | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 335,100 | 0 | - | - | Share Options (Right to Buy) | |
| Biohaven Ltd | Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 13 Nov 2025 | 333,333 | 740,546 | - | 7.5 | 2,499,998 | Common Shares |
| Biohaven Ltd | Vlad Coric | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 13 Nov 2025 | 333,333 | 1,195,275 | - | 7.5 | 2,499,998 | Common Shares |
| Metsera Inc | Matthew Lang | CHIEF LEGAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 325,000 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Brian Hubbard | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 319,186 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Clive A. Meanwell | Director, EXECUTIVE CHAIRMAN | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 297,907 | 0 | - | - | Stock Option (right to buy) | |
| Roivant Sciences Ltd | Vivek Ramaswamy | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 13 Nov 2025 | 287,283 | 35,221,076 | - | 20.8 | 5,978,359 | Common Shares |
| Alumis Inc | Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 5.25 per share. | 13 Nov 2025 | 276,179 | 276,179 | - | 5.3 | 1,449,940 | Common Stock |
| Cricut Inc (Class A) | Ashish Arora | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 275,000 | 2,943,146 | - | 0 | Class A Common Stock | |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 261,144 | 12,589,287 | - | - | Stock Options | |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 13 Nov 2025 | 261,144 | 0 | - | 8.1 | 2,104,821 | Class A Common Stock |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 13 Nov 2025 | 261,144 | 261,144 | - | 0.8 | 206,304 | Class A Common Stock |
| Metsera Inc | Christopher J. Visioli | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 255,349 | 0 | - | - | Stock Option (right to buy) | |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 250,000 | 4,689,362 | - | 0 | Class V Common Stock | |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 250,000 | 4,689,362 | - | - | ADK Class A Units | |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Sale of securities on an exchange or to another person at price $ 3.92 per share. | 13 Nov 2025 | 250,000 | 82,634 | - | 3.9 | 979,375 | Class A Common Stock |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 250,000 | 332,634 | - | 0 | Class A Common Stock | |
| Direct Digital Holdings Inc (Class A) | Mark D. Walker | Director, Chairman and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.21 per share. | 13 Nov 2025 | 245,008 | 0 | - | 0.2 | 51,452 | Class A Common Stock, par value $0.001 per share |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 234,742 | 721,789 | - | 0 | Class A Common Stock | |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 234,742 | 234,742 | - | - | Restricted Stock Units | |
| Confluent Inc (Class A) | Edward Jay Kreps | Director, CHIEF EXECUTIVE OFFICER | 13 Nov 2025 | 232,500 | 14,482,500 | - | - | Class B Common Stock | ||
| Confluent Inc (Class A) | Edward Jay Kreps | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 13 Nov 2025 | 232,500 | 377,074 | - | 23.5 | 5,470,725 | Class A Common Stock |
| Confluent Inc (Class A) | Edward Jay Kreps | Director, CHIEF EXECUTIVE OFFICER | 13 Nov 2025 | 232,500 | 609,574 | - | - | Class A Common Stock | ||
| Gevo Inc | Carol J. Battershell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 13 Nov 2025 | 224,639 | 353,862 (2%) | 1% | 0.7 | 150,508 | Common Stock |
| Gevo Inc | Carol J. Battershell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 224,639 | 0 | - | - | Stock Option | |
| Metsera Inc | Paul L. Berns | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 223,430 | 0 | - | - | Stock Option (right to buy) | |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 13 Nov 2025 | 221,555 | 221,555 | - | 0.8 | 175,028 | Class A Common Stock |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 221,555 | 12,850,431 | - | - | Stock Options | |
| Venture Global Inc (Class A) | Keith Larson | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 8.16 per share. | 13 Nov 2025 | 221,555 | 0 | - | 8.2 | 1,807,889 | Class A Common Stock |
| Maravai LifeSciences Holdings Inc (Class A) | Bernd Brust | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.25 per share. | 13 Nov 2025 | 216,212 | 466,771 | - | 3.3 | 702,689 | Class A Common Stock |
| Adient PLC | Jerome J. Dorlack | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 212,765 | 653,790 (0%) | 0% | - | Ordinary Shares | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,473,367 (26%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,660,867 (27%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,848,367 (27%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,660,867 (27%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,473,367 (26%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 187,500 | 18,848,367 (27%) | 0% | 37.0 | 6,941,888 | Common Stock | |
| Nano Nuclear Energy Inc | Jiang Yu | Director, President and Chairman, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 183,978 | 0 | - | - | Restricted Stock Units | |
| Kura Oncology Inc | Troy E. Wilson | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 182,500 | 429,353 (0%) | 0% | 0 | Common Stock | |
| D-Wave Quantum Inc | Alan Baratz | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 23.17 per share. | 13 Nov 2025 | 168,102 | 2,633,163 | - | 23.2 | 3,895,663 | Common Stock, par value $0.0001 per share ("Common Stock") |
| Surrozen Inc | Tim Kutzkey | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.65 per share. | 13 Nov 2025 | 167,307 | 962,718 | - | 12.7 | 2,116,434 | Common Stock |
| Metsera Inc | Christopher J. Visioli | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 150,000 | 0 | - | - | Stock Option (right to buy) | |
| Universal Electronics Inc | Richard K. Carnifax | COO and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 150,000 | 168,465 | - | - | Employee Stock Option (Rt to Buy) | |
| Universal Electronics Inc | Richard K. Carnifax | COO and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 150,000 | 392,433 | - | - | Performance Stock Units | |
| Universal Electronics Inc | Richard K. Carnifax | COO and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 150,000 | 242,433 | - | - | Performance Stock Units | |
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 148,953 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Joshua Pinto | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 148,953 | 0 | - | - | Stock Option (right to buy) | |
| Surrozen Inc | Tim Kutzkey | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.65 per share. | 13 Nov 2025 | 148,150 | 852,482 | - | 12.7 | 1,874,098 | Common Stock |
| Consol Energy Inc | James A. Brock | Director, Executive Chair and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 140,760 | 140,760 (0%) | 0% | 0 | Common stock, par value $0.01 per share | |
| Consol Energy Inc | James A. Brock | Director, Executive Chair and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 140,760 | 24,440 (0%) | 0% | 0 | Common stock, par value $0.01 per share | |
| Credit Acceptance Corp | Vinayak R. Hegde | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 140,000 | 140,502 (0%) | 0% | 0 | Common Stock | |
| Organon & Co. | Joseph T. Morrissey | Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 131,233 | 131,233 | - | - | Restricted Stock Units | |
| Circle Internet Grp Inc (Class A) | Rajeev V. Date | Director | Sale of securities on an exchange or to another person at price $ 83.00 per share. | 13 Nov 2025 | 127,245 | 190,869 | - | 83 | 10,561,335 | Class A Common Stock |
| LAVA Therapeutics NV | Fred M. Powell | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 124,700 | 0 | - | - | Share Options (Right to Buy) | |
| Metsera Inc | Steven Marso | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 120,000 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Brian Hubbard | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 120,000 | 0 | - | - | Stock Option (right to buy) | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,687,500 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,462,500 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Celsius Holdings Inc | William H. Milmoe | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,575,000 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 0 | - | - | Variable Prepaid Forward Sale Contract (obligation to sell) | ||
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,462,500 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,575,000 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Celsius Holdings Inc | Dean Desantis | Ten Percent Owner | 13 Nov 2025 | 112,500 | 1,687,500 (2%) | 0% | 37.0 | 4,165,133 | Common Stock | |
| Tyra Biosciences Inc | Daniel Bensen | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 13 Nov 2025 | 110,228 | 316,642 | - | 16.0 | 1,765,489 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 13 Nov 2025 | 109,031 | 4,000 | - | 38.1 | 4,158,442 | Common Stock |
| Metsera Inc | Brian Hubbard | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 106,395 | 0 | - | - | Stock Option (right to buy) | |
| Edgewell Personal Care Co | Rod R. Little | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 103,420 | 103,420 | - | - | Restricted Stock Equivalents 11/14/2025 | |
| AXT Inc | Gary L. Fischer | CFO | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 13 Nov 2025 | 101,297 | 361,997 (0%) | 0% | 10.1 | 1,026,949 | Common Stock |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.80 per share. | 13 Nov 2025 | 100,000 | 100,000 (0%) | 0% | 11.8 | 1,180,000 | Common Stock |
| Copart | Daniel J. Englander | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 100,000 | 0 | - | - | Stock Option | |
| Greenwich LifeSciences Inc | Snehal S. Patel | Director, CEO and CFO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 100,000 | 2,347,462 | - | - | Stock Options | |
| Marriott Vacations Worldwide Corp | Matthew E. Avril | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 100,000 | 100,000 | - | - | Stock Appreciation Right | |
| D-Wave Quantum Inc | John M. Markovich | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.17 per share. | 13 Nov 2025 | 98,060 | 1,482,874 | - | 23.2 | 2,272,482 | Common Stock, par value $0.0001 per share ("Common Stock") |
| Axon | Patrick W. Smith | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 97,015 | 3,120,997 (5%) | 0% | 0 | Common Stock | |
| Nano Nuclear Energy Inc | James Walker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 89,022 | 0 | - | - | Restricted Stock Units | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 87,100 | 64,265 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 13 Nov 2025 | 87,100 | 2,730,253 (10%) | 0% | 1.6 | 135,005 | Common Stock |
| Codexis Inc | Alison Moore | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 85,000 | 254,332 (0%) | 0% | 0 | Common Stock | |
| Circle Internet Grp Inc (Class A) | Jeremy Allaire | Director, Chairman and CEO | 13 Nov 2025 | 84,627 | 16,040,982 | - | - | Class B Common Stock | ||
| Circle Internet Grp Inc (Class A) | Jeremy Allaire | Director, Chairman and CEO | 13 Nov 2025 | 84,627 | 84,627 | - | - | Class A Common Stock | ||
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 13 Nov 2025 | 83,978 | 87,978 | - | 8.4 | 708,774 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 83,978 | 11,996 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mollie Leoni | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 82,500 | 240,939 (0%) | 0% | 0 | Common Stock | |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 80,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.70 per share. | 13 Nov 2025 | 80,000 | 134,691 (0%) | 0% | 2.7 | 215,600 | Common Stock |
| Progyny Inc | Peter Anevski | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 24.29 per share. | 13 Nov 2025 | 79,500 | 680,251 (0%) | 0% | 24.3 | 1,930,896 | Common Stock |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 78,247 | 547,731 | - | - | Performance Based Restricted Stock Units | |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 78,247 | 740,528 | - | 0 | Class A Common Stock | |
| Gevo Inc | Carol J. Battershell | Director | Sale of securities on an exchange or to another person at price $ 2.02 per share. | 13 Nov 2025 | 75,597 | 278,265 (1%) | 0% | 2.0 | 152,782 | Common Stock |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 75,000 | 4,614,362 | - | - | ADK Class A Units | |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Sale of securities on an exchange or to another person at price $ 3.91 per share. | 13 Nov 2025 | 75,000 | 82,634 | - | 3.9 | 293,093 | Class A Common Stock |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 75,000 | 157,634 | - | 0 | Class A Common Stock | |
| Indie Semiconductor Inc (Class A) | Ichiro Aoki | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 75,000 | 4,614,362 | - | 0 | Class V Common Stock | |
| Karman Holdings Inc | Jonathan Beaudoin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 63.69 per share. | 13 Nov 2025 | 74,000 | 666,861 | - | 63.7 | 4,712,875 | Common Stock |
| Emerson Electric | Surendralal Lanca Karsanbhai | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Emerson Electric | Surendralal Lanca Karsanbhai | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Emerson Electric | Surendralal Lanca Karsanbhai | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Emerson Electric | Surendralal Lanca Karsanbhai | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Emerson Electric | Surendralal Lanca Karsanbhai | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Axon | Joshua M. Isner | PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 67,910 | 306,289 (0%) | 0% | 0 | Common Stock | |
| Flotek Ind Inc | Harshavardhan V. Agadi | Director | Sale of securities on an exchange or to another person at price $ 14.71 per share. | 13 Nov 2025 | 66,956 | 197,265 (0%) | 0% | 14.7 | 984,648 | Common Shares |
| Hudson Global Inc | Jacob Zabkowicz | CEO Hudson Talent SolutionsLLC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 66,171 | 195,019 (6%) | 2% | 0 | Common Stock. | |
| Organon & Co. | Juliana Papa Drinane | Interim Head of Mfg & Supply | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 65,616 | 65,616 | - | - | Restricted Stock Units | |
| TE Connectivity | Terrence R. Curtin | Director, Chief Exec. Officer & Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 65,150 | 65,150 | - | - | Stock Option (Right to Buy) | |
| LAVA Therapeutics NV | Fred M. Powell | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 65,000 | 0 | - | - | Common Shares | |
| Circle Internet Grp Inc (Class A) | Rajeev V. Date | Director | Sale of securities on an exchange or to another person at price $ 84.73 per share. | 13 Nov 2025 | 63,622 | 127,247 | - | 84.7 | 5,390,692 | Class A Common Stock |
| Trump Media & Tech Grp Corp | Devin G. Nunes | Director, CEO, President, Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.18 per share. | 13 Nov 2025 | 62,058 | 1,374,371 | - | 12.2 | 755,798 | Common Stock, par value $0.0001 per share |
| Karman Holdings Inc | Stephanie Sawhill | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 63.93 per share. | 13 Nov 2025 | 62,000 | 504,939 | - | 63.9 | 3,963,623 | Common Stock |
| Adient PLC | Jian James Huang | EVP, APAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 60,512 | 0 | - | - | Restricted Stock Units | |
| Adient PLC | Jian James Huang | EVP, APAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 60,512 | 60,512 (0%) | 0% | 0 | Ordinary Shares | |
| Adient PLC | Jian James Huang | EVP, APAC | Sale or transfer of securities back to the company at price $ 20.02 per share. | 13 Nov 2025 | 60,512 | 0 (0%) | 0% | 20.0 | 1,211,450 | Ordinary Shares |
| Adient PLC | Mark A. Oswald | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 60,283 | 130,279 (0%) | 0% | - | Ordinary Shares | |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.99 per share. | 13 Nov 2025 | 59,508 | 662,281 | - | 3.0 | 177,929 | Class A Common Stock |
| Edgewell Personal Care Co | Rod R. Little | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 58,612 | 0 | - | - | Performance Stock Equivalents 11-11-2022 | |
| Edgewell Personal Care Co | Rod R. Little | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 58,612 | 392,985 (0%) | 0% | 0 | Common Stock | |
| Werewolf Therapeutics Inc | Luke B. Evnin | Director | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 13 Nov 2025 | 58,372 | 3,592,061 | - | 1.0 | 57,205 | Common Stock |
| Beauty Health Co (Class A) | Philippe Schaison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 57,692 | 57,692 | - | - | Class A Common Stock | |
| Aspen Aerogels Inc | Donald R. Young | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.23 per share. | 13 Nov 2025 | 56,845 | 494,011 (2%) | 0% | 3.2 | 183,609 | Common Stock |
| Angi Inc (Class A) | Jeffrey W. Kip | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 55,000 | 110,000 | - | - | Restricted Stock Units | |
| Angi Inc (Class A) | Jeffrey W. Kip | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 55,000 | 149,357 (0%) | 0% | - | Class A Common Stock, par value $0.001 | |
| Circle Internet Grp Inc (Class A) | Rajeev V. Date | Director | Sale of securities on an exchange or to another person at price $ 85.50 per share. | 13 Nov 2025 | 54,600 | 194,063 | - | 85.5 | 4,668,300 | Class A Common Stock |
| Primo Brands Corp (Class A) | Steven P. Stanbrook | Director | Purchase of securities on an exchange or from another person at price $ 16.43 per share. | 13 Nov 2025 | 54,540 | 181,601 | - | 16.4 | 895,945 | Class A Common Stock |
| Nano Nuclear Energy Inc | Jaisun Garcha | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 53,415 | 0 | - | - | Restricted Stock Units | |
| WPP PLC. (ADR) | Cindy Helen Rose | Executive Director,Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.89 per share. | 13 Nov 2025 | 50,000 | 58,000 (0%) | 0% | 2.9 | 144,350 | Ords 0.10p |
| WPP PLC. (ADR) | Philip Eric Rene Jansen | Non-Executive Director,Chairman | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 13 Nov 2025 | 50,000 | 50,000 (0%) | 0% | 2.9 | 142,550 | Ords 0.10p |
| TriplePoint Venture Growth BDC Corp | James P. Labe | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.94 per share. | 13 Nov 2025 | 50,000 | 717,352 (2%) | 0% | 5.9 | 296,885 | Common Stock |
| TriplePoint Venture Growth BDC Corp | Sajal K. Srivastava | Director, President and CIO | Purchase of securities on an exchange or from another person at price $ 5.94 per share. | 13 Nov 2025 | 50,000 | 717,352 (2%) | 0% | 5.9 | 296,885 | Common Stock |
| Marriott Vacations Worldwide Corp | Matthew E. Avril | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 50,000 | 52,981 (0%) | 0% | 0 | Common Stock | |
| Celldex Therapeutics Inc | Richard M. Wright | Former Officer | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 13 Nov 2025 | 49,298 | 20,833 (0%) | 0% | 24.0 | 1,183,177 | Common Stock |
| Kura Oncology Inc | Kathleen Ford | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 48,900 | 112,275 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Teresa Brophy Bair | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 48,900 | 196,943 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 48,900 | 148,576 (0%) | 0% | 0 | Common Stock | |
| Metsera Inc | Jon P. Stonehouse | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 47,730 | 0 | - | - | Stock Option (right to buy) | |
| Adient PLC | Jian James Huang | EVP, APAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 47,281 | 47,281 | - | - | Restricted Stock Units | |
| Adient PLC | James D. Conklin | EVP, Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 47,281 | 99,110 (0%) | 0% | - | Ordinary Shares | |
| Metsera Inc | Matthew Lang | CHIEF LEGAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 46,875 | 0 | - | - | Stock Option (right to buy) | |
| TriplePoint Venture Growth BDC Corp | James P. Labe | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.99 per share. | 13 Nov 2025 | 46,700 | 764,052 (2%) | 0% | 6.0 | 279,789 | Common Stock |
| TriplePoint Venture Growth BDC Corp | Sajal K. Srivastava | Director, President and CIO | Purchase of securities on an exchange or from another person at price $ 5.99 per share. | 13 Nov 2025 | 46,700 | 764,052 (2%) | 0% | 6.0 | 279,789 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 13 Nov 2025 | 42,765 | 22,576 | - | 37.0 | 1,584,016 | Common Stock |
| Adient PLC | Heather M. Tiltmann | EVP, CLO, CHRO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 42,553 | 135,141 (0%) | 0% | - | Ordinary Shares | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 58,500 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 108,500 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.5 | 103,750 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.2 | 91,300 | Common Stock |
| Scotts Miracle-Gro Co (Class A) | James Hagedorn | Director, Chairman & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 41,353 | 121,307 (0%) | 0% | 0 | Common Shares | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 40,287 | 76,184 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 13 Nov 2025 | 40,287 | 44,287 | - | 17.9 | 720,332 | Common Stock |
| Somnigroup Intl Inc | David Montgomery | EVP Global Business Strategy | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 40,000 | 843,839 (1%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 39,769 | 63,781 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.52 per share. | 13 Nov 2025 | 39,769 | 77,630 (0%) | 0% | 86.5 | 3,440,814 | Common Stock |
| Werewolf Therapeutics Inc | Luke B. Evnin | Director | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Nov 2025 | 39,560 | 3,552,501 | - | 0.9 | 36,791 | Common Stock |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Sale of securities on an exchange or to another person at price $ 23.19 per share. | 13 Nov 2025 | 39,272 | 23,355 (0%) | 0% | 23.2 | 910,702 | Common Stock |
| Schlumberger | Stephane Biguet | EVP & CFO | Sale of securities on an exchange or to another person at price $ 36.75 per share. | 13 Nov 2025 | 38,447 | 175,690 (0%) | 0% | 36.7 | 1,412,927 | Common Stock, $0.01 Par Value Per Share |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Sale of securities on an exchange or to another person at price $ 71.33 per share. | 13 Nov 2025 | 38,438 | 21,993 (0%) | 0% | 71.3 | 2,741,783 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 37,494 | 62,506 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 13 Nov 2025 | 37,494 | 81,781 | - | 21.8 | 816,244 | Common Stock |
| Werewolf Therapeutics Inc | Luke B. Evnin | Director | Sale of securities on an exchange or to another person at price $ 0.95 per share. | 13 Nov 2025 | 36,621 | 3,515,880 | - | 1.0 | 34,790 | Common Stock |
| Artivion Inc | James Patrick Mackin | President & CEO | Sale of securities on an exchange or to another person at price $ 45.86 per share. | 13 Nov 2025 | 34,210 | 800,993 (2%) | 0% | 45.9 | 1,568,802 | Common Stock |
| Circle Internet Grp Inc (Class A) | P. Sean Neville | Director | Sale of securities on an exchange or to another person at price $ 85.05 per share. | 13 Nov 2025 | 33,569 | 33,568 | - | 85.0 | 2,855,043 | Class A Common Stock |
| LAVA Therapeutics NV | Peter A. Kiener | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Karen J. Wilson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Kapil Dhingra | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Jay T. Backstrom | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Mary E. Wadlinger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Christy J. Oliger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| Metsera Inc | Clive A. Meanwell | Director, EXECUTIVE CHAIRMAN | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 32,250 | 0 | - | - | Stock Option (right to buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 440.30 per share. | 13 Nov 2025 | 32,234 | 45,396 (0%) | 0% | 440.3 | 14,192,630 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 31,250 | 118,750 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 13 Nov 2025 | 31,250 | 113,031 | - | 22.1 | 689,688 | Common Stock |
| Axon | Brittany Bagley | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 30,560 | 121,652 (0%) | 0% | 0 | Common Stock | |
| Lineage Inc | Robb A. LeMasters | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 33.74 per share. | 13 Nov 2025 | 30,000 | 60,000 | - | 33.7 | 1,012,197 | Common Stock |
| LAVA Therapeutics NV | Kapil Dhingra | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 30,000 | 0 | - | - | Common Shares | |
| Adient PLC | Stephanie S. Marianos | EVP, Global IT & Bus. Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 29,550 | 75,563 (0%) | 0% | - | Ordinary Shares | |
| Amphenol (Class A) | David M Silverman | Senior VP, Human Resources | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 29,012 | 29,012 | - | - | Stock Option-Trust | |
| Amphenol (Class A) | David M Silverman | Senior VP, Human Resources | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 29,012 | 116,048 | - | - | Stock Option | |
| Arbor Realty Trust Inc | Ivan Kaufman | Director, COB, CEO and President | Purchase of securities on an exchange or from another person at price $ 8.34 per share. | 13 Nov 2025 | 29,000 | 54,000 (0%) | 0% | 8.3 | 241,860 | Common Stock, par value $0.01 per share |
| Scotts Miracle-Gro Co (Class A) | Nathan Eric Baxter | President and COO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 28,510 | 79,238 (0%) | 0% | 0 | Common Shares | |
| Grindr Inc (Class A) | Zachary Katz | GC and Head of Global Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.10 per share. | 13 Nov 2025 | 28,437 | 504,301 | - | 15.1 | 429,399 | Common Stock |
| Adient PLC | Jerome J. Dorlack | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.02 per share. | 13 Nov 2025 | 28,212 | 633,137 (0%) | 0% | 20.0 | 564,804 | Ordinary Shares |
| Circle Internet Grp Inc (Class A) | Rajeev V. Date | Director | Sale of securities on an exchange or to another person at price $ 85.04 per share. | 13 Nov 2025 | 28,000 | 195,082 | - | 85.0 | 2,381,120 | Class A Common Stock |
| Direct Digital Holdings Inc (Class A) | Mark D. Walker | Director, Chairman and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 13 Nov 2025 | 27,492 | 245,008 | - | 0.4 | 10,172 | Class A Common Stock, par value $0.001 per share |
| Cadre Holdings Inc | Brad Williams | PRESIDENT | Sale of securities on an exchange or to another person at price $ 43.62 per share. | 13 Nov 2025 | 27,370 | 78,719 | - | 43.6 | 1,193,879 | Common Stock, par value $0.0001 per share ("Common Stock") |
| Atlas Lithium Corp | Marc Fogassa | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 4.45 per share. | 13 Nov 2025 | 27,272 | 4,607,468 | - | 4.5 | 121,409 | Common Stock |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 27,269 | 27,269 | - | - | Restricted Stock Units | |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 27,269 | 747,961 | - | 0 | Class A Common Stock | |
| Edgewell Personal Care Co | Rod R. Little | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.39 per share. | 13 Nov 2025 | 27,167 | 365,818 (0%) | 0% | 18.4 | 499,601 | Common Stock |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 27,052 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.63 per share. | 13 Nov 2025 | 27,052 | 50,407 (0%) | 0% | 8.6 | 233,459 | Common Stock |
| Acushnet Holdings Corp | David Maher | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 79.32 per share. | 13 Nov 2025 | 26,887 | 852,143 (1%) | 0% | 79.3 | 2,132,801 | Common Stock |
| Celldex Therapeutics Inc | Richard M. Wright | Former Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 26,672 | 0 | - | - | Incentive Stock Option | |
| Celldex Therapeutics Inc | Richard M. Wright | Former Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.38 per share. | 13 Nov 2025 | 26,672 | 54,381 (0%) | 0% | 10.4 | 276,855 | Common Stock |
| Edgewell Personal Care Co | Francesca Weissman | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 26,476 | 26,476 | - | - | Restricted Stock Equivalents 11-14-2025 | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 35.80 per share. | 13 Nov 2025 | 26,166 | 65,341 | - | 35.8 | 936,743 | Common Stock |
| Angi Inc (Class A) | Jeffrey W. Kip | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.18 per share. | 13 Nov 2025 | 25,003 | 124,354 (0%) | 0% | 11.2 | 279,534 | Class A Common Stock, par value $0.001 |
| Nerdy Inc (Class A) | Gregory Mrva | Director | Sale of securities on an exchange or to another person at price $ 0.85 per share. | 13 Nov 2025 | 25,000 | 685,991 | - | 0.9 | 21,250 | Class A Common Stock |
| Nerdy Inc (Class A) | Gregory Mrva | Director | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 13 Nov 2025 | 25,000 | 710,991 | - | 0.9 | 22,250 | Class A Common Stock |
| Par Pacific Holdings Inc | William C. Pate | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 25,000 | 499,610 (0%) | 0% | 0 | Common Stock | |
| Snowflake Inc (Class A) | Benoit Dageville | Director, Founder and Chief Architect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 25,000 | 192,927 | - | - | Stock Option (Right to Buy) | |
| Snowflake Inc (Class A) | Benoit Dageville | Director, Founder and Chief Architect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.48 per share. | 13 Nov 2025 | 25,000 | 75,519 | - | 13.5 | 337,000 | Common Stock |
| Snowflake Inc (Class A) | Benoit Dageville | Director, Founder and Chief Architect | Sale of securities on an exchange or to another person at price $ 264.45 per share. | 13 Nov 2025 | 25,000 | 50,519 | - | 264.5 | 6,611,250 | Common Stock |
| Arbor Realty Trust Inc | Ivan Kaufman | Director, COB, CEO and President | Purchase of securities on an exchange or from another person at price $ 9.10 per share. | 13 Nov 2025 | 25,000 | 25,000 (0%) | 0% | 9.1 | 227,500 | Common Stock, par value $0.01 per share |
| Kura Oncology Inc | Thomas Doyle | SVP, Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 24,967 | 134,796 (0%) | 0% | 0 | Common Stock | |
| Edgewell Personal Care Co | LaTanya Langley | Chief People & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 24,270 | 24,270 | - | - | Restricted Stock Equivalents 11-14-2025 | |
| Metsera Inc | Paul L. Berns | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 24,188 | 0 | - | - | Stock Option (right to buy) | |
| Franklin Covey Co. | Paul S. Walker | Director, CEO, Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 23,716 | 131,929 (0%) | 0% | 0 | Common shares | |
| PSQ Holdings Inc (Class A) | Michael Robert Hebert | Chief People Officer | Sale of securities on an exchange or to another person at price $ 1.55 per share. | 13 Nov 2025 | 23,310 | 239,843 | - | 1.6 | 36,131 | Class A Common Stock, par value $0.0001 per share |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 13 Nov 2025 | 23,242 | 2,643,153 (9%) | 0% | 7.5 | 173,402 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 21,867 | 4,479 (0%) | 0% | 5.5 | 119,612 | Common Stock |
| ARS Pharma Inc | Brian T. Dorsey | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 13 Nov 2025 | 21,828 | 32,617 | - | 0.6 | 13,970 | Common Stock |
| ARS Pharma Inc | Brian T. Dorsey | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 21,828 | 0 | - | - | Stock Option (Right to Buy) | |
| ARS Pharma Inc | Brian T. Dorsey | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.71 per share. | 13 Nov 2025 | 21,828 | 10,789 | - | 8.7 | 190,050 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 441.35 per share. | 13 Nov 2025 | 21,330 | 24,066 (0%) | 0% | 441.4 | 9,413,996 | Common Stock |
| Metsera Inc | Steven Marso | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 21,279 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Christopher J. Visioli | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 21,250 | 0 | - | - | Common Stock | |
| Metsera Inc | Christopher J. Visioli | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 21,250 | 21,250 | - | - | Restricted Stock Unit | |
| Metsera Inc | Christopher Whitten Bernard | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 21,250 | 21,250 | - | - | Restricted Stock Unit | |
| Metsera Inc | Christopher Whitten Bernard | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 21,250 | 0 | - | - | Common Stock | |
| TE Connectivity | Heath A. Mitts | Director, EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Axon | Jeffrey C. Kunins | CPO & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 20,618 | 94,563 (0%) | 0% | 0 | Common Stock | |
| D-Wave Quantum Inc | Diane Nguyen | EVP, Chief Legal Officer & GC | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 13 Nov 2025 | 20,000 | 568,845 | - | 23.7 | 473,282 | Common Stock, par value $0.0001 per share ("Common Stock") |
| WillScot Mobile Mini Holdings Corp | Jeffrey Sagansky | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 20,000 | 2,415,216 (2%) | 0% | 0 | Common Stock | |
| EVgo Inc (Class A) | Badar Khan | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.99 per share. | 13 Nov 2025 | 19,836 | 720,692 | - | 3.0 | 59,310 | Class A Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 13 Nov 2025 | 19,688 | 43,714 (0%) | 0% | 91.0 | 1,792,592 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 19,688 | 13,836 | - | - | Stock Option (Right to Buy) | |
| Bridgewater Bancshares Inc | Mary Jayne Crocker | EVP & CHIEF STRATEGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 18,898 | 91,102 | - | - | Option to buy | |
| Bridgewater Bancshares Inc | Mary Jayne Crocker | EVP & CHIEF STRATEGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.47 per share. | 13 Nov 2025 | 18,898 | 217,923 (0%) | 0% | 7.5 | 141,168 | Common Stock |
| Trump Media & Tech Grp Corp | Vladimir Novachki | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.18 per share. | 13 Nov 2025 | 18,601 | 617,615 | - | 12.2 | 226,473 | Common Stock, par value $0.0001 per share |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.72 per share. | 13 Nov 2025 | 18,576 | 4,000 | - | 37.7 | 700,687 | Common Stock |
| Tyra Biosciences Inc | Daniel Bensen | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.11 per share. | 13 Nov 2025 | 18,572 | 298,070 | - | 16.1 | 299,191 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 440.22 per share. | 13 Nov 2025 | 18,528 | 25,186 (0%) | 0% | 440.2 | 8,156,396 | Common Stock |
| P10 Inc (Class A) | Edwin Poston | Director, See remarks | 13 Nov 2025 | 18,427 | 18,427 | - | - | Class A Common Stock | ||
| P10 Inc (Class A) | Edwin Poston | Director, See remarks | 13 Nov 2025 | 18,427 | 116,024 | - | - | Class B Common Stock | ||
| P10 Inc (Class A) | Edwin Poston | Director, See remarks | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 13 Nov 2025 | 18,427 | 0 | - | 9.0 | 166,175 | Class A Common Stock |
| Amphenol (Class A) | David M Silverman | Senior VP, Human Resources | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 18,343 | 18,343 | - | - | Stock Option-Trust | |
| Amphenol (Class A) | David M Silverman | Senior VP, Human Resources | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 18,343 | 73,375 | - | - | Stock Option | |
| Scotts Miracle-Gro Co (Class A) | James Hagedorn | Director, Chairman & CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.40 per share. | 13 Nov 2025 | 18,216 | 103,091 (0%) | 0% | 58.4 | 1,063,814 | Common Shares |
| Vyome Holdings Inc | John M. Tincoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 17,833 | 17,833 | - | - | Stock Option (right to buy) | |
| Vyome Holdings Inc | Stanley D. Pomichter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 17,833 | 17,833 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Steven Marso | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 17,000 | 17,000 | - | - | Restricted Stock Unit | |
| Metsera Inc | Steven Marso | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 17,000 | 0 | - | - | Common Stock | |
| Metsera Inc | Brian Hubbard | CHIEF SCIENTIFIC OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 17,000 | 0 | - | - | Common Stock | |
| Metsera Inc | Brian Hubbard | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 17,000 | 17,000 | - | - | Restricted Stock Unit | |
| Amphastar Pharma Inc | Floyd F. Petersen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.69 per share. | 13 Nov 2025 | 16,679 | 92,210 (0%) | 0% | 16.7 | 278,373 | Common Stock |
| Amphastar Pharma Inc | Floyd F. Petersen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 16,679 | 0 | - | - | Stock Option (right to buy) | |
| Amphastar Pharma Inc | Floyd F. Petersen | Director | Sale of securities on an exchange or to another person at price $ 26.49 per share. | 13 Nov 2025 | 16,679 | 75,531 (0%) | 0% | 26.5 | 441,837 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 16,250 | 4,479 (0%) | 0% | 5.5 | 88,888 | Common stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 13 Nov 2025 | 16,250 | 20,729 (0%) | 0% | 1.2 | 19,988 | Common stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 16,250 | 48,750 | - | - | Stock option (right to buy) | |
| Metsera Inc | Kristina M. Burow | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 16,125 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Joshua Pinto | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 16,125 | 0 | - | - | Stock Option (right to buy) | |
| Wave Life Sciences Ltd | Adrian Rawcliffe | Director | Sale of securities on an exchange or to another person at price $ 6.79 per share. | 13 Nov 2025 | 16,115 | 12,700 (0%) | 0% | 6.8 | 109,421 | Ordinary Shares |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.62 per share. | 13 Nov 2025 | 16,100 | 47,099 (0%) | 0% | 36.6 | 589,582 | Common Stock |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 16,100 | 25,300 | - | - | Employee Stock Option (right to buy) | |
| Axon | Cameron Brooks | CHIEF REVENUE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 15,810 | 60,278 (0%) | 0% | 0 | Common Stock | |
| Celldex Therapeutics Inc | Richard M. Wright | Former Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.48 per share. | 13 Nov 2025 | 15,750 | 70,131 (0%) | 0% | 22.5 | 354,060 | Common Stock |
| Celldex Therapeutics Inc | Richard M. Wright | Former Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 15,750 | 7,875 | - | - | Incentive Stock Option | |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.04 per share. | 13 Nov 2025 | 15,600 | 42,591 (0%) | 0% | 2.0 | 31,777 | Common Stock |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 15,600 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kura Oncology Inc | Mollie Leoni | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.18 per share. | 13 Nov 2025 | 15,485 | 225,454 (0%) | 0% | 11.2 | 173,074 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Nov 2025 | 15,000 | 15,000 | - | 10.2 | 153,000 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 15,000 | 17,900 | - | - | Stock Option | |
| Abeona Therapeutics Inc | Mark J. Alvino | Director | Sale of securities on an exchange or to another person at price $ 4.74 per share. | 13 Nov 2025 | 15,000 | 62,252 (0%) | 0% | 4.7 | 71,168 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 63.14 per share. | 13 Nov 2025 | 14,774 | 1,274,873 | - | 63.1 | 932,830 | Common Stock |
| Viavi Soln Inc | Keith L. Barnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Richard E. Belluzzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Donald A. Colvin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Joanne Solomon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Douglas L. Gilstrap | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Laura A. Black | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Viavi Soln Inc | Eugenia M. Corrales | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 14,369 | 14,369 | - | - | Restricted Stock Unit | |
| Hudson Global Inc | Jacob Zabkowicz | CEO Hudson Talent SolutionsLLC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.03 per share. | 13 Nov 2025 | 14,306 | 180,713 (6%) | 0% | 10.0 | 143,489 | Common Stock. |
| L3Harris Tech | Christopher E. Kubasik | Director, Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 14,171 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| L3Harris Tech | Christopher E. Kubasik | Director, Chair and CEO | Sale of securities on an exchange or to another person at price $ 301.05 per share. | 13 Nov 2025 | 14,171 | 144,426 (0%) | 0% | 301.1 | 4,266,180 | Common Stock, Par Value $1.00 |
| L3Harris Tech | Christopher E. Kubasik | Director, Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 162.30 per share. | 13 Nov 2025 | 14,171 | 158,597 (0%) | 0% | 162.3 | 2,299,953 | Common Stock, Par Value $1.00 |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,835 | 1 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 13 Nov 2025 | 13,835 | 37,861 (0%) | 0% | 91.1 | 1,259,677 | Common Stock |
| Grindr Inc (Class A) | Zachary Katz | GC and Head of Global Affairs | Sale of securities on an exchange or to another person at price $ 14.39 per share. | 13 Nov 2025 | 13,781 | 490,520 | - | 14.4 | 198,309 | Common Stock |
| 3M | Zoe L. Dickson | EVP & Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,629 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| 3M | Zoe L. Dickson | EVP & Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 138.39 per share. | 13 Nov 2025 | 13,629 | 19,790 (0%) | 0% | 138.4 | 1,886,117 | Common Stock |
| Capital One | Frank G. LaPrade | Chief Enterprise Srvcs Officer | Sale of securities on an exchange or to another person at price $ 222.41 per share. | 13 Nov 2025 | 13,564 | 48,315 (0%) | 0% | 222.4 | 3,016,769 | Common Stock |
| Therealreal Inc | Steve Lo | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.27 per share. | 13 Nov 2025 | 13,542 | 331,768 (0%) | 0% | 14.3 | 193,244 | Common Stock |
| Therealreal Inc | Steve Lo | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,542 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Therealreal Inc | Steve Lo | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.64 per share. | 13 Nov 2025 | 13,542 | 345,310 (0%) | 0% | 7.6 | 103,461 | Common Stock |
| Trump Media & Tech Grp Corp | Scott Glabe | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.17 per share. | 13 Nov 2025 | 13,496 | 325,236 | - | 12.2 | 164,302 | Common Stock, par value $0.0001 per share |
| Farmer Bros. Co. | Matthew Coffman | VP and Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,333 | 90,000 | - | - | Cash-Settled Restricted Stock Units | |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.82 per share. | 13 Nov 2025 | 13,332 | 60,431 (0%) | 0% | 50.8 | 677,532 | Common Stock |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,332 | 6,668 | - | - | Employee Stock Option (right to buy) | |
| Bank of America | Dean C. Athanasia | Co-President | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 13,250 | 560,094 (0%) | 0% | 0 | Common Stock | |
| Scotts Miracle-Gro Co (Class A) | Nathan Eric Baxter | President and COO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.40 per share. | 13 Nov 2025 | 12,702 | 66,536 (0%) | 0% | 58.4 | 741,797 | Common Shares |
| TE Connectivity | Aaron K. Stucki | Pres. Transportation Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 12,600 | 12,600 | - | - | Stock Option (Right to Buy) | |
| Metsera Inc | Matthew Lang | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 12,500 | 12,500 | - | - | Restricted Stock Unit | |
| Metsera Inc | Matthew Lang | CHIEF LEGAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 12,500 | 0 | - | - | Common Stock | |
| Franklin Covey Co. | Jessica G. Betjemann | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 12,406 | 15,342 (0%) | 0% | 0 | Common shares | |
| Scotts Miracle-Gro Co (Class A) | Chris Hagedorn | EVP & Chief of Staff | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 12,258 | 66,334 (0%) | 0% | 0 | Common Shares | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 12,220 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 13 Nov 2025 | 12,220 | 62,627 (0%) | 0% | 7.5 | 91,772 | Common Stock |
| Nerdwallet Inc (Class A) | Samuel Yount | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.34 per share. | 13 Nov 2025 | 12,129 | 389,622 | - | 14.3 | 173,930 | Class A Common Stock |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.37 per share. | 13 Nov 2025 | 12,100 | 54,691 (0%) | 0% | 2.4 | 28,725 | Common Stock |
| Super Micro Computer | George Kao | SVP, OPERATIONS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 12,100 | 0 | - | - | Employee Stock Option (right to buy) | |
| TE Connectivity | Shadrak W. Kroeger | Pres., Industrial Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 11,700 | 11,700 | - | - | Stock Option (Right to Buy) | |
| Scotts Miracle-Gro Co (Class A) | Mark J. Scheiwer | EVP, CFO & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 11,520 | 20,159 (0%) | 0% | 0 | Common Shares | |
| Nano Nuclear Energy Inc | Florent Heidet | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 11,277 | 0 | - | - | Restricted Stock Units | |
| Acushnet Holdings Corp | David Maher | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 80.02 per share. | 13 Nov 2025 | 11,240 | 881,686 (1%) | 0% | 80.0 | 899,471 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 13 Nov 2025 | 11,000 | 47,781 (0%) | 0% | 135.4 | 1,489,620 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 11,000 | 11,000 | - | - | Stock Option | |
| Oshkosh Corp | Mahesh Narang | Exec VP & Pres., Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 10,881 | 10,882 | - | - | Restricted Stock Units | |
| Oshkosh Corp | Mahesh Narang | Exec VP & Pres., Access | Grant, award, or other acquisition of securities at price $ 124.28 per share. | 13 Nov 2025 | 10,881 | 26,793 (0%) | 0% | 124.3 | 1,352,248 | Common Stock |
| Acushnet Holdings Corp | David Maher | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 79.25 per share. | 13 Nov 2025 | 10,625 | 892,926 (1%) | 0% | 79.3 | 842,072 | Common Stock |
| Apollo Global (Class A) (New) | Scott M. Kleinman | Director, Co-President (See Remarks) | Grant, award, or other acquisition of securities at price $ 129.64 per share. | 13 Nov 2025 | 10,136 | 75,831 (0%) | 0% | 129.6 | 1,314,031 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Sale of securities on an exchange or to another person at price $ 45.81 per share. | 13 Nov 2025 | 10,115 | 4,885 | - | 45.8 | 463,351 | Common Stock |
| Energy Vault Holdings Inc | Robert Piconi | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 13 Nov 2025 | 10,000 | 20,207,242 | - | 3.0 | 29,958 | Common Stock |
| Marriott Vacations Worldwide Corp | Charles Elliott Andrews | Director | Purchase of securities on an exchange or from another person at price $ 47.01 per share. | 13 Nov 2025 | 10,000 | 41,435 (0%) | 0% | 47.0 | 470,100 | Common Stock |
| Celsius Holdings Inc | Hal Kravitz | Director | Purchase of securities on an exchange or from another person at price $ 45.24 per share. | 13 Nov 2025 | 10,000 | 216,147 (0%) | 0% | 45.2 | 452,400 | Common Stock, $0.001 par value per share |
| Crown Crafts Inc | Donald Ratajczak | Director | Purchase of securities on an exchange or from another person at price $ 2.74 per share. | 13 Nov 2025 | 10,000 | 311,181 (3%) | 0% | 2.7 | 27,450 | Common Stock |
| Crown Crafts Inc | Donald Ratajczak | Director | Purchase of securities on an exchange or from another person at price $ 2.80 per share. | 13 Nov 2025 | 10,000 | 331,181 (3%) | 0% | 2.8 | 28,000 | Common Stock |
| Crown Crafts Inc | Donald Ratajczak | Director | Purchase of securities on an exchange or from another person at price $ 2.69 per share. | 13 Nov 2025 | 10,000 | 321,181 (3%) | 0% | 2.7 | 26,900 | Common Stock |
| HF Foods Grp Inc | Jeffery L. Taylor | Director | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 13 Nov 2025 | 10,000 | 10,000 (0%) | 0% | 2.3 | 22,500 | Common Stock |
| LAVA Therapeutics NV | Karen J. Wilson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 10,000 | 0 | - | - | Common Shares | |
| Nukkleus Inc - Ordinary Shares - New | Reuven Yeganeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 10,000 | 20,000 | - | 0 | Common Stock, $0.0001 par value per share | |
| Tredegar Corp | William M. Gottwald | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 13 Nov 2025 | 9,998 | 744,948 (2%) | 0% | 8.5 | 85,143 | Tredegar Common Stock |
| Tredegar Corp | John D. Gottwald | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 13 Nov 2025 | 9,997 | 744,949 (2%) | 0% | 8.5 | 85,134 | Tredegar Common Stock |
| Energy Vault Holdings Inc | Akshay Ladwa | Chief Operations Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.54 per share. | 13 Nov 2025 | 9,886 | 1,857,689 | - | 3.5 | 34,996 | Common Stock |
| Scotts Miracle-Gro Co (Class A) | Dimiter Todorov | EVP, CLO & CORPORATE SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 9,748 | 25,416 (0%) | 0% | 0 | Common Shares | |
| H.B. Fuller Co | Nathan D. Weaver | Exec VP, Business Transform. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.38 per share. | 13 Nov 2025 | 9,546 | 16,516 (0%) | 0% | 33.4 | 318,645 | Common Stock |
| H.B. Fuller Co | Nathan D. Weaver | Exec VP, Business Transform. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 9,546 | 0 | - | - | Employee Stock Option (Right-to-Buy) | |
| Circle Internet Grp Inc (Class A) | Rajeev V. Date | Director | Sale of securities on an exchange or to another person at price $ 86.16 per share. | 13 Nov 2025 | 9,500 | 185,582 | - | 86.2 | 818,520 | Class A Common Stock |
| TE Connectivity | John S. Jenkins | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 9,450 | 9,450 | - | - | Stock Option (Right to Buy) | |
| Hyliion Holdings Corporation | Jon T. Panzer | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.70 per share. | 13 Nov 2025 | 9,406 | 892,225 | - | 1.7 | 15,990 | Common Stock |
| PSQ Holdings Inc (Class A) | Michael Robert Hebert | Chief People Officer | Purchase of securities on an exchange or from another person at price $ 1.61 per share. | 13 Nov 2025 | 9,400 | 252,876 | - | 1.6 | 15,102 | Class A Common Stock, par value $0.0001 per share |
| CuriosityStream Inc - Ordinary Shares- Class A | Jonathan S. Huberman | Director | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 13 Nov 2025 | 9,291 | 1,224,285 | - | 5 | 46,455 | Common Stock |
| Adtalem Global Education Inc | Stephen W. Beard | Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.26 per share. | 13 Nov 2025 | 9,204 | 450,530 (0%) | 0% | 96.3 | 885,977 | Common Stock |
| Ashland Inc | Guillermo Novo | Director, Chair of the Board and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 9,119 | 9,119 | - | - | Restricted Stock Unit | |
| Ashland Inc | Guillermo Novo | Director, Chair of the Board and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.51 per share. | 13 Nov 2025 | 9,119 | 141,107 (0%) | 0% | 51.5 | 469,720 | Common Stock |
| Hyliion Holdings Corporation | Joshua T. Mook | Chief Technology Officer | Other type of transaction at price $ 1.66 per share. | 13 Nov 2025 | 9,039 | 507,572 | - | 1.7 | 15,005 | Common Stock |
| Ashland Inc | Guillermo Novo | Director, Chair of the Board and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.10 per share. | 13 Nov 2025 | 9,029 | 135,767 (0%) | 0% | 53.1 | 479,440 | Common Stock |
| Ashland Inc | Guillermo Novo | Director, Chair of the Board and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 9,029 | 18,060 | - | - | Restricted Stock Unit | |
| Green Dot Corp (Class A) | Jess Unruh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 9,017 | 223,699 (0%) | 0% | 0 | Class A Common Stock | |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.47 per share. | 13 Nov 2025 | 9,000 | 30,999 (0%) | 0% | 44.5 | 400,230 | Common Stock |
| Monster Beverage | Guy P. Carling | President of EMEA & OSP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 9,000 | 6,000 | - | - | Employee Stock Option (right to buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 8,970 | 151,365 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 13 Nov 2025 | 8,970 | 2,666,395 (9%) | 0% | 1.6 | 13,904 | Common Stock |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 11.18 per share. | 13 Nov 2025 | 8,887 | 139,689 (0%) | 0% | 11.2 | 99,329 | Common Stock |
| Kura Oncology Inc | Teresa Brophy Bair | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 11.18 per share. | 13 Nov 2025 | 8,804 | 188,139 (0%) | 0% | 11.2 | 98,401 | Common Stock |
| Redwire Corp | Peter Cannito | Director, Chairman and CEO | Purchase of securities on an exchange or from another person at price $ 5.71 per share. | 13 Nov 2025 | 8,750 | 535,478 | - | 5.7 | 49,962 | Common Stock, par value $0.0001 per share |
| 3M | Zoe L. Dickson | EVP & Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 8,750 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| 3M | Zoe L. Dickson | EVP & Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 154.04 per share. | 13 Nov 2025 | 8,750 | 14,911 (0%) | 0% | 154.0 | 1,347,850 | Common Stock |
| Charles Schwab | Paula A. Sneed | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2025 | 8,680 | 96,974 (0%) | 0% | 0 | Common Stock | |
| ANI Pharma Inc | Patrick D. Walsh | Director | Sale of securities on an exchange or to another person at price $ 86.88 per share. | 13 Nov 2025 | 8,643 | 61,405 (0%) | 0% | 86.9 | 750,904 | Common Stock |
| FS Bancorp Inc | Marina Cofer-Wildsmith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.08 per share. | 13 Nov 2025 | 8,543 | 5,590 (0%) | 0% | 40.1 | 342,403 | Common Stock |
| Carlyle Secured Lending Inc | Thomas M. Hennigan | Director, CFO | Purchase of securities on an exchange or from another person at price $ 12.04 per share. | 13 Nov 2025 | 8,400 | 96,894 (0%) | 0% | 12.0 | 101,136 | Common Stock |
| Trump Media & Tech Grp Corp | Phillip Juhan | CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.17 per share. | 13 Nov 2025 | 8,334 | 301,518 | - | 12.2 | 101,445 | Common Stock, par value $0.0001 per share |
| Adient PLC | Gregory S. Smith | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 8,274 | 30,818 (0%) | 0% | - | Ordinary Shares | |
| Old National Bancorp | Daniel S. Hermann | Director | Grant, award, or other acquisition of securities at price $ 20.79 per share. | 13 Nov 2025 | 8,177 | 64,448 (0%) | 0% | 20.8 | 170,000 | Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.